AD251

Establishing Multidisciplinary Clinical Pathways for Selecting and Sequencing Systemic Treatments for Moderate to Severe Atopic Dermatitis

Train the Trainer

Nearly half of patients with atopic dermatitis (AD) have moderate to severe disease with symptoms that negatively affect their sleep, mental health, and overall quality of life. Although the clinical heterogeneity of AD is increasingly recognized, failure to assess AD in routine clinical practice can lead to delayed diagnosis, underappreciation of disease severity, and delays in treatment initiation.

Topical therapies can be very effective in treating mild cases of AD, but patients with moderate to severe disease generally require systemic therapy to achieve long-term disease control. The discovery of the role of type 2 inflammatory pathways in AD has led to new concepts in AD pathogenesis, and subsequently, to novel treatment strategies. Yet evidence indicates that there is discordance between patients’ and clinicians’ perception of severity and disease burden, and many patients report inadequate disease control with current treatments.

To personalize treatment of moderate to severe AD, clinicians must continually assess and adapt to evolving diagnostic and therapeutic strategies to ensure proactive, targeted, and patient-centric treatment to improve outcomes. To support translation and implementation of the latest evidence into routine clinical practice, this training program, modeled on the CDC Training of Trainers approach, provides learners with the tools and resources to facilitate peer-to-peer learning with their interprofessional clinical teams.

Faculty: Jonathan Silverberg, MD, PhD, MPH, Kelly Dugan, PharmD, BCPS, CSP

Release Date: September 19, 2025

Expiration Date: September 19, 2026